MAPT and Alzheimer disease: Therefore, the combination of CSF biomarkers (Aβ42, Aβ40 T-tau, P-tau181) and their ratio (Aβ42/Aβ40 or also T-tau/Aβ42, P-tau181/Aβ42) increase the performance and allow AD diagnosis at earlier stages of disease [7].